Altre lingue Daré Bioscience, Inc.

Azioni

DARE

US23666P1012

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
0,3059 ^USD	+5,77%		+9,25%	-1,00%

23/04	Daré Bioscience, Inc. annuncia il pagamento di una sovvenzione per sostenere l'ulteriore sviluppo della nuova tecnologia contraccettiva DARE-LARC1	CI
28/03	Transcript : Daré Bioscience, Inc., 2023 Earnings Call, Mar 28, 2024

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1	23/04
Daré Bioscience, Inc. Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1	23/04
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive	11/04
Daré Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update	28/03
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024	21/03
Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting	22/02
Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024	31/01
Daré Bioscience, Inc. Announces Positive End-Of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024	31/01
Daré Bioscience, Inc. Announces Executive Changes	26/01
Daré Bioscience, Inc. Announces the Resignation of Lisa Walters-Hoffert as Chief Financial Officer	26/01
Dare Bioscience Says Chief Financial Officer Retiring, Chief Commercial Officer Has Resigned	26/01
Daré Bioscience Announces Executive Team and Board of Directors Changes	26/01
Daré Bioscience Announces Grant to Support Biotherapeutic Product Development	17/01
Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases	04/01
Daré Bioscience Secures $12 million in Royalty-backed Investment Structure	26/12
Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study	20/12
Dare Bioscience, Inc. Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the Dare-Pdm1 Phase 1 Clinical Study	20/12
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study	13/12
Dare Bioscience Obtains FDA Clearance for Phase 2 Trial of Potential Dyspareunia Treatment	07/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Daré Bioscience, Inc.

Azioni

DARE

US23666P1012

Altre lingue

Filtri